Src kinase inhibitor compounds

Abstract From the Canadian patent

Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts hydrates, solvates, crystal forms and individual diastereomers and , pharmaceutical compositions including the same which are inhibitors of , tyrosine kinase enzymes and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders such as immune , diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role such as , cancer, angiogensis, atherosclerosis graft rejection, rheumatoid arthritis and psoriasis.